Verastem Oncology
Presence
Verastem Oncology is a company listed under the stock ticker VSTM (US).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Verastem Oncology
- Dan Paterson, President and Chief Executive Officer
- Michael Kauffman, Lead Director
- Brian Stuglik, Director
Popular executive movements at Verastem Oncology
- John Hayslip has joined the company as Chief Medical Officer (posted on April 19 2024).
- Mike Crowther has joined the company as Chief Commercial and Business Strategy Officer (posted on October 27 2023).
- Dan Calkins, who was Vice President, Finance, is promoted to Chief Financial Officer (posted on October 27 2023).
Create your alert
to follow the executive moves at Verastem Oncology.
Biotechnology
Verastem Oncology has 2,292 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
Popular contacts in Biotechnology
News
Press releases by Verastem Oncology
- Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference | Verastem Inc.
- Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer | Verastem Inc.
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Verastem Inc.
- Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs | Verastem Inc.
- Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates | Verastem Inc.
- Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer | Verastem Inc.
- Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers | Verastem Inc.
- Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress | Verastem Inc.
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Verastem Inc.
- Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer | Verastem Inc.
- View more press releases Close
Social media about Verastem Oncology
- Verastem Oncology on Wikipedia, Google News & Yahoo Finance
- Verastem Oncology on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Dan Paterson 
Call Verastem Oncology at +1 617...
